Pappas Capital makes one of its ‘most successful exits’ in Merck $2.75B deal for startup
Drug giant Merck is paying $2.75 billion in cash for a biotech startup, VelosBio, which had landed two investments from Pappas Capital. And the deal is a big one for Pappas.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
